Medidata Blog

Translating Quality and Risk Assessment for Risk-Based Monitoring at SCOPE Summit

Reading Time: < 1 minute

This year, SCOPE Summit hosted the Cambridge Healthtech Institute’s inaugural conference "From QbD and Risk Assessment to Risk-Based Monitoring (RBM) — Laying the Foundation." Medidata's Kyle Given moderated one of the sessions, featuring Boehringer Ingelheim's Andy Lawton and CRA Consultant Mary Mills. In this video recap, Kyle shares his takeaways and why he believes that RBM is the wave of the future when it comes to clinical trials' execution.

*Kyle Given is a principal in Medidata’s strategic consulting services group, supporting clients with risk-based monitoring programs.

TWEET THIS:

VIDEO: Translating Quality and Risk Assessment for Risk-Based Monitoring (RBM) @SCOPESummit http://t.co/t7UXD64ev0 #SCOPE2015 #clinicaltrial

— Medidata (@Medidata) March 6, 2015

Medidata Solutions Image

Medidata Solutions